Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Glioblastoma × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Prostatic Neoplasms 5 Neoplasms 4 Neoplasm Metastasis 4 Advanced Solid Tumors 4 Leukemia, Myeloid, Acute 3 Triple Negative Breast Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Recurrent Squamous Cell Lung Carcinoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Kidney Neoplasms 1 Glioma 1 Glioblastoma 1 Fanconi Anemia, Complementation Group D1 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Childhood Solid Tumors 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Breast Adenocarcinoma 1 Advanced Solid Tumor 1 Advanced Ovarian Cancer 1

Interventions

Temozolomide 186 Radiotherapy 109 Bevacizumab 84 Radiation 37 Irinotecan 26 Magnetic Resonance Spectroscopy 25 Carmustine 23 Surgical Procedures, Operative 21 Lomustine 19 Erlotinib Hydrochloride 18 Chemotherapy, Adjuvant 15 Carboplatin 15 sargramostim 11 Drug Therapy 11 temsirolimus 10 Radiosurgery 10 O(6)-benzylguanine 10 pembrolizumab 9 motexafin gadolinium 9 Vorinostat 9 Radiotherapy, Intensity-Modulated 9 Radiotherapy, Conformal 9 Imatinib Mesylate 9 Everolimus 9 Thalidomide 8 Sorafenib 8 Nivolumab 8 Gefitinib 8 cediranib 7 Sirolimus 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04740190 2025-06-11

TAC-GReD

The University of Hong Kong

Phase 2 Completed

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡